Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies
Current Fungal Infection Reports · 2026-12 · 20 (1)
DOI: 10.1007/s12281-026-00532-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Fungal Infection Reports, online erschienen am 27.04.2026. Verfasst von Katarina Popovic und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Oklahoma Health Campus, Oklahoma City, OK, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS, National Institutes of Health/National Center for Research Resources, Colorado Clinical Translational Science Institute.
Abstract (Originalsprache)
Purpose of Review The aim of this review is to provide an in-depth overview of chromoblastomycosis, with emphasis on emerging management strategies and therapeutic options, and to underscore potential gaps in the literature and priorities for future research. Recent Findings Among the newer triazoles, posaconazole has demonstrated greatest therapeutic potential in the treatment of chromoblastomycosis, including for severe and refractory disease. Adjunctive immunomodulatory therapies such as glucan, imiquimod, and acitretin have shown potential as well. Several novel and repurposed agents also have potential activity against dematiaceous fungi, including tricyclazole, HIV peptidase inhibitors, 1,10-phenanthroline-5,6-dione, and benzimidazoles. A recently proposed combination protocol with debulking, intralesional amphotericin B, and oral terbinafine (DAT protocol) achieved cure in all 16 included patients in a 2025 case series. While excisional surgery remains the preferred physical therapeutic modality, several reports have shown favorable results with both photodynamic and heat therapy. Summary Chromoblastomycosis continues to pose a therapeutic challenge, requiring prolonged antifungal therapy often combined with physical therapeutic modalities. Improved access to diagnostics and early intervention remain essential to reducing global disease burden.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Oklahoma Health Campus, Oklahoma City, OK, USA.
- Department of Medicine, Division of Infectious Diseases, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
- Núcleo de Medicina Tropical, University of Brasília, Brasilia, Brazil.
- Centro de Pesquisas em Medicina Tropical de Rondônia, Porto Velho, Brazil.
- The Centre Hospitalier Universitaire de Soins et de Santé Publique d'Analakely, Antananarivo, Madagascar.
- Division of Infectious Diseases, Department of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK, USA.
Förderung
- NCRR NIH HHS
- National Institutes of Health/National Center for Research Resources, Colorado Clinical Translational Science Institute
Zitieren
APA
Popovic, K., Henao-Martínez, A. F., Teixeira, M. M., de Souza, E. B. A., Rakotoarisaona, M., & Agudelo Higuita, N. I. (2026). Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies. Current Fungal Infection Reports, 20(1). https://doi.org/10.1007/s12281-026-00532-3
Vancouver
Popovic K, Henao-Martínez AF, Teixeira MM, de Souza EBA, Rakotoarisaona M, Agudelo Higuita NI. Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies. Current Fungal Infection Reports. 2026;20(1). doi:10.1007/s12281-026-00532-3
BibTeX
@article{Popovic2026,
author = {Popovic, Katarina and Henao-Martínez, Andrés F and Teixeira, Marcus de Melo and de Souza, Elton Bill Amaral and Rakotoarisaona, Mendrika and Agudelo Higuita, Nelson Iván},
title = {Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies},
journal = {Current Fungal Infection Reports},
year = {2026},
volume = {20},
number = {1},
doi = {10.1007/s12281-026-00532-3}
}
EUVIMED